P Marks

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells
    P A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 92:1210-6. 2000
  2. ncbi request reprint Histone deacetylase inhibitors as new cancer drugs
    P A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Oncol 13:477-83. 2001
  3. ncbi request reprint Histone deacetylases and cancer: causes and therapies
    P Marks
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Rev Cancer 1:194-202. 2001
  4. ncbi request reprint The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Cell Cycle 3:534-5. 2004
  5. ncbi request reprint Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid
    William Kevin Kelly
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 2:150-7. 2005
  6. ncbi request reprint Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects
    Wei Sheng Xu
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 65:7832-9. 2005
  7. ncbi request reprint Prospects: histone deacetylase inhibitors
    Milos Dokmanovic
    Memorial Sloan Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research New York City, New York 10021, USA
    J Cell Biochem 96:293-304. 2005
  8. ncbi request reprint Novel histone deacetylase inhibitors in the treatment of thyroid cancer
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 11:3958-65. 2005
  9. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
  10. ncbi request reprint Histone deacetylase inhibitors: discovery and development as anticancer agents
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research, New York City, New York 10021, USA
    Expert Opin Investig Drugs 14:1497-511. 2005

Collaborators

Detail Information

Publications36

  1. ncbi request reprint Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells
    P A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 92:1210-6. 2000
    ..The hydroxamic acid-based HPCs are potentially effective agents for cancer therapy and, possibly, cancer chemoprevention...
  2. ncbi request reprint Histone deacetylase inhibitors as new cancer drugs
    P A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Oncol 13:477-83. 2001
    ..Several structurally different histone deacetylase inhibitors are in phase I or II clinical trials in patients with cancers...
  3. ncbi request reprint Histone deacetylases and cancer: causes and therapies
    P Marks
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Rev Cancer 1:194-202. 2001
    ..HDAC inhibitors are proving to be an exciting therapeutic approach to cancer, but how do they exert this effect?..
  4. ncbi request reprint The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Cell Cycle 3:534-5. 2004
    ..Gui et al. have identified effects of SAHA on p21(WAF1) promotor associated proteins that explain, at least in part, the selective effects of HDAC in altering gene expression...
  5. ncbi request reprint Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid
    William Kevin Kelly
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 2:150-7. 2005
    ..SAHA is one of the HDAC inhibitors most advanced in development. It is in phase I and II clinical trials for patients with both hematologic and solid tumors...
  6. ncbi request reprint Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects
    Wei Sheng Xu
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 65:7832-9. 2005
    ..The present findings indicate that the HDAC inhibitor could exert antitumor effects by inducing polyploidy, and this effect is more marked in transformed cells with nonfunctioning p21WAF1 or p53 genes...
  7. ncbi request reprint Prospects: histone deacetylase inhibitors
    Milos Dokmanovic
    Memorial Sloan Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research New York City, New York 10021, USA
    J Cell Biochem 96:293-304. 2005
    ..The answers to these questions will have therapeutic importance since we will identify targets for enhancing the efficacy and safety of HDACi...
  8. ncbi request reprint Novel histone deacetylase inhibitors in the treatment of thyroid cancer
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 11:3958-65. 2005
    ..g., anaplastic and medullary thyroid carcinomas) for which limited, if any, therapeutic options are available...
  9. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
    ..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...
  10. ncbi request reprint Histone deacetylase inhibitors: discovery and development as anticancer agents
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research, New York City, New York 10021, USA
    Expert Opin Investig Drugs 14:1497-511. 2005
    ..HDAC inhibitors can induce cancer cell death, whereas normal cells are relatively resistant to HDAC inhibitor-induced cell death...
  11. pmc Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor
    Weisheng Xu
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 103:15540-5. 2006
    ..Identifying these differences can have predictive value in assessing therapeutic response and identifying targets to enhance therapeutic efficacy...
  12. pmc A man who has made his Marks on science
    Karen Honey
    J Clin Invest 116:2833. 2006
  13. pmc Thioredoxin in cancer--role of histone deacetylase inhibitors
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Semin Cancer Biol 16:436-43. 2006
    ..Up-regulation of TBP-2 and decrease of Trx may contribute to the sensitivity of many hematologic and solid tumors to anti-cancer activity of HDACi...
  14. ncbi request reprint Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Biotechnol 25:84-90. 2007
    ..A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma. More potent analogs of SAHA have shown unacceptable toxicity...
  15. ncbi request reprint Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
    Deborah L Marrocco
    Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide, Hanson Institute, Adelaide, South Australia 5000, Australia
    Mol Cancer Ther 6:51-60. 2007
    ..Consequently, combinatorial treatments that target different components of the AR pathway may afford a more effective strategy to control the growth of prostate cancer cells...
  16. pmc Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
    R K Lindemann
    Cancer Immunology Program, The Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 104:8071-6. 2007
    ..Our studies provide important information regarding the mechanisms of action of HDACi that have broad implications regarding stratification of patients receiving HDACi therapy alone or in combination with other anticancer agents...
  17. ncbi request reprint Histone deacetylase inhibitors selectively suppress expression of HDAC7
    Milos Dokmanovic
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Mol Cancer Ther 6:2525-34. 2007
    ..Selective down-regulation of HDAC7 protein may serve as a marker of response of tumors to HDACi...
  18. ncbi request reprint Histone deacetylase inhibitors: overview and perspectives
    Milos Dokmanovic
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cancer Res 5:981-9. 2007
    ..A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death...
  19. ncbi request reprint Histone deacetylase inhibitors in programmed cell death and cancer therapy
    Paul A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cell Cycle 4:549-51. 2005
    ..In this review, we discuss the study of HDAC inhibitors in cell death and cancer research, the implications of our recent findings, and some outstanding questions that need to be addressed...
  20. pmc Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors
    Melissa J Peart
    The Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne 3002, Victoria, Australia
    Proc Natl Acad Sci U S A 102:3697-702. 2005
    ....
  21. pmc Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
    Yufang Shao
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:18030-5. 2004
    ..Induction of autophagic cell death by HDAC inhibitors has clear clinical implications in treating cancers with apoptotic defects...
  22. ncbi request reprint Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors
    Leonard A Cohen
    Div Nutrition and Endocrinology, American Health Foundation, Valhalla, NY 10595, USA
    Anticancer Res 22:1497-504. 2002
    ..The results of this animal model study indicate that SAHA, when fed in the diet, serves as both a chemopreventive and chemotherapeutic agent in the absence of any detectable side effects...
  23. pmc The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
    Lisa M Butler
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:11700-5. 2002
    ....
  24. ncbi request reprint Histone deacetylase inhibitors: from target to clinical trials
    William K Kelly
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Investig Drugs 11:1695-713. 2002
    ..Several HDAC inhibitors are currently in clinical trials as anticancer agents and, in particular, hydroxamic acid-based HDAC inhibitors have shown activity against cancers at well-tolerated doses...
  25. ncbi request reprint Molecular sequelae of histone deacetylase inhibition in human malignant B cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 101:4055-62. 2003
    ....
  26. pmc Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease
    Emma Hockly
    Medical and Molecular Genetics, Guy s, King s and St Thomas School of Medicine, King s College London, Eighth Floor Guy s Tower, Guy s Hospital, London SE1 9RT, United Kingdom
    Proc Natl Acad Sci U S A 100:2041-6. 2003
    ..SAHA dramatically improved the motor impairment in R6/2 mice, clearly validating the pursuit of this class of compounds as HD therapeutics...
  27. ncbi request reprint Histone deacetylases
    Paul A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Curr Opin Pharmacol 3:344-51. 2003
    ..Results of clinical trials with several of these agents have indicated that they are well tolerated at doses that have anti-tumour activity...
  28. ncbi request reprint Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
    Wm Kevin Kelly
    Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 9:3578-88. 2003
    ..To evaluate the safety, pharmacokinetics, and biological activity of suberoylanilide hydroxamic acid (SAHA) administered by 2-h i.v. infusion in patients with advanced cancer...
  29. ncbi request reprint Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro
    Martha C Kutko
    Department of Pediatric Surgery, Sloan Kettering Institute and Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:5749-55. 2003
    ..The effects of two of these agents, suberoylanilide hydroxamic acid (SAHA) and suberoyl-3-aminopyridineamide hydroxamic acid (pyroxamide), were investigated for their growth-suppressive effects on rhabdomyosarcoma (RMS) cells...
  30. ncbi request reprint Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo
    Victoria M Richon
    Discovery Biology, Aton Pharma, Inc, Tarrytown, New York 10591, USA
    Methods Enzymol 376:199-205. 2004
  31. ncbi request reprint Histone deacetylase inhibitors
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Adv Cancer Res 91:137-68. 2004
    ..2001; Kelly et al., 2002a,b; Piekarz et al., 2001; Wozniak et al., 1999)...
  32. pmc The American Society for Clinical Investigation--the first 100 years
    Paul A Marks
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Clin Invest 118:1223-4. 2008
    ....
  33. pmc Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:540-5. 2004
    ..These findings highlight the pleiotropic antitumor effects of HDAC inhibition, and provide the framework for future clinical applications of SAHA to improve patient outcome in MM...
  34. ncbi request reprint Histone deacetylase inhibitors: development as cancer therapy
    Paul A Marks
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
    Novartis Found Symp 259:269-81; discussion 281-8. 2004
    ....
  35. ncbi request reprint Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid
    Christopher M Reilly
    Department of Biomedical Sciences and Pathobiology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University and Edward Via College of Osteopathic Medicine, Blacksburg, 24060, USA
    J Immunol 173:4171-8. 2004
    ..These data indicate that SAHA blocks mesangial cell inflammatory mediator production in vitro and disease progression in vivo in MRL/lpr mice...
  36. pmc Blasts from the past
    Paul A Insel
    J Clin Invest 114:1017-33. 2004
    ....